Calculator for ovarian carcinoma subtype prediction
- PMID: 21131918
- DOI: 10.1038/modpathol.2010.215
Calculator for ovarian carcinoma subtype prediction
Abstract
With the emerging evidence that the five major ovarian carcinoma subtypes (high-grade serous, clear cell, endometrioid, mucinous, and low-grade serous) are distinct disease entities, management of ovarian carcinoma will become subtype specific in the future. In an effort to improve diagnostic accuracy, we set out to determine if an immunohistochemical panel of molecular markers could reproduce consensus subtype assignment. Immunohistochemical expression of 22 biomarkers were examined on tissue microarrays constructed from 322 archival ovarian carcinoma samples from the British Columbia Cancer Agency archives, for the period between 1984 and 2000, and an independent set of 242 cases of ovarian carcinoma from the Gynaecologic Tissue Bank at Vancouver General Hospital from 2001 to 2008. Nominal logistic regression was used to produce a subtype prediction model for each of these sets of cases. These models were then cross-validated against the other cohort, and then both models were further validated in an independent cohort of 81 ovarian carcinoma samples from five different centers. Starting with data for 22 markers, full model fit, backwards, nominal logistic regression identified the same nine markers (CDKN2A, DKK1, HNF1B, MDM2, PGR, TFF3, TP53, VIM, WT1) as being most predictive of ovarian carcinoma subtype in both the archival and tumor bank cohorts. These models were able to predict subtype in the respective cohort in which they were developed with a high degree of sensitivity and specificity (κ statistics of 0.88±0.02 and 0.86±0.04, respectively). When the models were cross-validated (ie using the model developed in one case series to predict subtype in the other series), the prediction equation's performances were reduced (κ statistics of 0.70±0.04 and 0.61±0.04, respectively) due to differences in frequency of expression of some biomarkers in the two case series. Both models were then validated on the independent series of 81 cases, with very good to excellent ability to predict subtype (κ=0.85±0.06 and 0.78±0.07, respectively). A nine-marker immunohistochemical maker panel can be used to objectively support classification into one of the five major subtypes of ovarian carcinoma.
Similar articles
-
The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors.Mod Pathol. 2013 Sep;26(9):1255-63. doi: 10.1038/modpathol.2013.55. Epub 2013 Apr 5. Mod Pathol. 2013. PMID: 23558569
-
Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium.Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1677-86. doi: 10.1158/1055-9965.EPI-13-0391. Epub 2013 Jul 23. Cancer Epidemiol Biomarkers Prev. 2013. PMID: 23880734 Free PMC article.
-
Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.PLoS Med. 2008 Dec 2;5(12):e232. doi: 10.1371/journal.pmed.0050232. PLoS Med. 2008. PMID: 19053170 Free PMC article.
-
Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.Pathology. 2011 Aug;43(5):420-32. doi: 10.1097/PAT.0b013e328348a6e7. Pathology. 2011. PMID: 21716157 Review.
-
Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.Oncology (Williston Park). 2016 Feb;30(2):166-76. Oncology (Williston Park). 2016. PMID: 26892153 Review.
Cited by
-
Differentially methylated loci distinguish ovarian carcinoma histological types: evaluation of a DNA methylation assay in FFPE tissue.Biomed Res Int. 2013;2013:815894. doi: 10.1155/2013/815894. Epub 2013 Sep 24. Biomed Res Int. 2013. PMID: 24175302 Free PMC article. Clinical Trial.
-
Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours.Nat Commun. 2015 Jun 17;6:7419. doi: 10.1038/ncomms8419. Nat Commun. 2015. PMID: 26080861 Free PMC article.
-
Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.J Pathol. 2022 Apr;256(4):388-401. doi: 10.1002/path.5849. Epub 2022 Feb 7. J Pathol. 2022. PMID: 34897700 Free PMC article.
-
Cancer of the ovary, fallopian tube, and peritoneum: 2021 update.Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(Suppl 1):61-85. doi: 10.1002/ijgo.13878. Int J Gynaecol Obstet. 2021. PMID: 34669199 Free PMC article. Review.
-
A comprehensive analysis of the expression, epigenetic and genetic changes of HNF1B and ECI2 in 122 cases of high-grade serous ovarian carcinoma.Oncol Lett. 2021 Mar;21(3):185. doi: 10.3892/ol.2021.12446. Epub 2021 Jan 6. Oncol Lett. 2021. PMID: 33574924 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous